WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 12, 2018--
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that Jay R. Luly, Ph.D., President and Chief Executive Officer, will
present at the following investor conferences:
- LEERINK Partners 7th Annual Global Healthcare Conference,
New York City
February 14, 10:30 a.m. ET
2018 RBC Capital Markets Global Healthcare Conference, New York City
21, 3:35 p.m. ET
A live webcast of each presentation will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of Enanta’s
website at www.enanta.com.
A replay of the webcasts will be available following the presentation
and will be archived for approximately 60 days.
Enanta Pharmaceuticals has used its robust, chemistry-driven approach
and drug discovery capabilities to become a leader in the discovery of
small molecule drugs for the treatment of viral infections and liver
diseases. Two protease inhibitors, glecaprevir and paritaprevir,
discovered and developed through Enanta’s collaboration with AbbVie,
have now been approved in jurisdictions around the world as part of
AbbVie’s direct-acting antiviral (DAA) regimens for the treatment of
hepatitis C virus (HCV) infection, including the U.S.-marketed regimens
MAVYRET™ (glecaprevir/pibrentasvir) and VIEKIRA PAK®
Royalties from the AbbVie collaboration are helping to fund Enanta’s
research and development efforts, which are currently focused on the
following disease targets: non-alcoholic steatohepatitis (NASH), primary
biliary cholangitis (PBC), respiratory syncytial virus (RSV) and
hepatitis B virus (HBV). Please visit www.enanta.com
for more information.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180212005326/en/
Source: Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc.